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Background: Cervical dystonia (CD) involves painful involuntary contraction of the neck and 
shoulder muscles and abnormal posture in middle-aged adults. Botulinum neurotoxin type A 
(BoNT-A) is effective in treating CD but little is known about its associated cost-effectiveness.
Objective: To evaluate the cost-effectiveness of abobotulinumtoxinA for treating CD from 
the UK payer perspective.
Methods: A Markov model was developed to evaluate the cost-effectiveness of abobotulinum-
toxinA versus best supportive care (BSC) in CD, with a lifetime horizon and health states for 
response, nonresponse, secondary nonresponse, and BSC in patients with CD (mean age: 
53 years; 37% male). Clinical improvement measured using Toronto Western Spasmodic Tor-
ticollis Rating Scale (TWSTRS) was mapped to utility using data from a randomized trial of 
abobotulinumtoxinA. Health care resource use, costs, and other inputs were from the British 
National Formulary, Personal Social Services Research Unit, published literature, or expert 
opinion. Costs and outcomes were discounted at 3.5% per annum.
Results: In the base case, the incremental lifetime quality-adjusted life-years (QALYs) gained 
from abobotulinumtoxinA arm versus BSC was 0.253 per patient, whereas the incremental cost 
was £7,160, leading to an incremental cost-effectiveness ratio (ICER) of £30,468 per QALY. 
One-way sensitivity analyses showed that these results were sensitive to the proportion of 
responders to abobotulinumtoxinA at first injection, duration between injections, the number 
of reinjections allowed among primary nonresponders, and any difference in baseline TWSTRS 
value between the BSC and abobotulinumtoxinA arms. Probabilistic sensitivity analysis showed 
that abobotulinumtoxinA was cost-effective 46% and 49% of times at thresholds of £20,000 
and £30,000 per QALY, respectively. Scenarios are considered including vial-sharing, produc-
tivity losses, secondary response/nonresponse at subsequent injections, 5-year time horizon, 
and alternative reinjection intervals for BoNT-As produced ICERs ranging from cost-saving to 
£40,777 per QALY, versus BSC.
Conclusion: AbobotulinumtoxinA was found to be cost-effective in treating adults with CD, 
at acceptable willingness-to-pay thresholds in the UK.
Keywords: cost-effectiveness analysis, cervical dystonia, botulinum neurotoxin type A, 
abobotulinumtoxinA
Introduction
Dystonia is a disorder that causes involuntary contraction of skeletal muscles, abnormal 
posture, and severe pain or discomfort. Dystonia may be more common than evidence 
suggests, owing to under-recognition, misdiagnosis, or late clinical presentation.1,2 
Cervical dystonia (CD) is the most commonly reported type and mainly affects neck 
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and shoulder muscles in middle-aged patients.3–5 CD’s preva-
lence in Europe seems to exceed than elsewhere (e.g., up to 
233 cases per 1,000,000 population6 vs 89 per 1,000,000 in 
the US7). Within the UK specifically, data have suggested 
that there are up to 24,000 cases8 although, interestingly, a 
much higher estimate (up to 70,000 cases) has been proposed 
by the Dystonia Society.9 Data on the associated economic 
burden of CD are scarce. However, 6-month costs for the US 
have been estimated as $1,255 to $63,320.8 Evidence on lost 
productivity due to work absenteeism is also sparse, although 
employment statistics show that at least one-third of patients 
with CD stop working as the disease progresses.10
Conventional therapeutic options for CD include skeletal 
muscle relaxants, anticholinergics, and rehabilitative therapy. 
In addition, some patients need deep brain stimulation 
therapy and selective peripheral denervation.4 Pharmaco-
therapy involving botulinum neurotoxin type A (BoNT-A) 
injection has also proven effective11,12 for CD, especially 
when combined with conventional therapy. By reducing 
muscle force, such treatment can alleviate pain, increase 
the range of free movement, and improve resting posture. 
Consequently, BoNT-A therapy can reduce the everyday care 
burden of managing CD13 and also improves patients’ and 
potentially, caregivers’ quality of life (QoL). BoNT-A usage 
for CD has also been shown to result in productivity-related 
gains through decreased absenteeism and sickness leave.14 
Also, another study found that, compared with patients on 
oral medications, more of those on BoNT-A treatments 
had improvement in employment status (oral medications: 
18.5%; BoNT-As: 66.1%) and restoration of full employment 
with normal productivity (oral medications: 0%; BoNT-As: 
12.9%).15 Such results may reflect BoNT-As’ ability to reduce 
pain and bring about functional improvements in patients with 
CD, given the strong association between pain and physical 
dysfunction with job impairment.16
These findings invite questions about the comparative 
effects of the various BoNT-As available. Currently, three 
such products are used for CD in the UK: abobotulinum-
toxinA (Dysport®: Ipsen Limited, Slough, UK), onabotu-
linumtoxinA (Botox®: Allergan Limited, Marlow, UK), and 
incobotulinumtoxinA (Xeomin®: Merz Pharmaceuticals 
GmbH, Frankfurt/Main, Germany). Of note, although no 
published head-to-head trials have compared the effective-
ness of these BoNT-As, a recent mixed treatment comparison 
reported similar improvements in scores on the Toronto West-
ern Spasmodic Torticollis Rating Scale (TWSTRS; which 
comprises three independently scored subscales [severity, 
disability, pain] , with the three scores being summed to give 
the TWSTRS total score [range 0–87, best to worst]17).18,19 
However, evidence also suggests that these BoNT-As differ 
in key characteristics, including time to first improvement, 
maximum benefit derived by patients, duration of symp-
tomatic relief, and costs.8,20 This lack of clarity about the 
relative merits of different BoNT-As in CD is echoed by 
other key unknowns regarding these drugs. In particular, 
despite the significant costs of CD to the UK National 
Health Service(NHS),8 there are no published UK data on 
the associated productivity losses of patients not treated with 
BoNT-As nor on the cost-effectiveness of these treatments. 
Little or no evidence exists on cost-effectiveness of BoNT-As 
for CD in the UK, although one study21 showed BoNT-As to 
be cost-effective over a 1-year time horizon relative to BSC 
from the US government perspective.
With such data gaps in mind, we used economic model-
ing to assess the cost-effectiveness of abobotulinumtoxinA 
and other BoNT-As versus best supportive care (BSC) as 
treatment for CD, from the perspective of the UK NHS and 
Personal Social Services (PSS). For these purposes, BSC 
comprised oral medications (including benzodiazepines, 
baclofen, and anticholinergic agents), deep brain stimulation, 
and selective peripheral denervation.
Methods
Overview
Ethical permission was not required for this study as it was 
based purely on secondary data. A Markov model22,23 with a 
3-month cycle duration was developed in Microsoft Excel® 
(2010) to predict the costs, benefits, and incremental cost-
effectiveness ratios (ICERs) per life-year and quality-adjusted 
life-year (QALY) from initiation of BoNT-A therapy or BSC 
over an analytic time horizon (lifetime in base case; varied 
in scenario analyses) or until death. The analysis adopted 
the perspective of the UK NHS and PSS. Model costs and 
outcomes were discounted at 3.5% per annum based on the 
National Institute for Health and Care Excellence reference 
case.24 The currency year for the analyses was 2013.
Key characteristics of the population in the model were 
intended to closely match those in an abobotulinumtoxinA 
trial.25 In this study, the mean age was 53.0 years (standard 
deviation [SD]: 13.0 years); 37% were males and the mean 
baseline total TWSTRS score was 44.9 (SD: 8.4). As there 
is no evidence that CD increases mortality risk, the model 
calculated age-specific mortality using interim life tables 
from the UK Office for National Statistics.26
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Model structure
Figure 1 presents the model structure for the BoNT-A and 
BSC arms, which was informed by consultation with clinical 
experts. In the BoNT-A arm, patients with CD starting active 
treatment are divided into two health states: “no response” 
or “response.” Response was defined as an improvement in 
TWSTRS from baseline of at least 20% at week 4 or 8 or 
12, in the base case (higher improvement in TWSTRS from 
baseline (≥30%) has been tested as part of alternative scenario 
analysis). Owing to unavailability of data, it was assumed 
that patients not responding to the initial injection do not 
achieve response in subsequent injection cycles. Similarly, 
patients who respond to the initial injection are assumed not 
to develop secondary nonresponse. Accordingly, only the 
first injection cycle determines the number of responding 
and nonresponding patients throughout the model. In an 
alternative scenario, the model assumed that nonresponders 
could achieve response with subsequent reinjections given 
at higher doses. Before treatment discontinuation, nonre-
sponders are allowed up to six BoNT-A reinjections (with 
electromyographic or ultrasound guidance) before moving 
to BSC. Initial responders were allowed to receive up to 
Figure 1 Model structure.
Notes: *Level of response is based on average change of TWSTRS from baseline in the three groups from trial reanalysis. TWSTRS and quality of life are tracked for each 
health state. All patients at any state are at risk of death.
Abbreviations: BSC, best supportive care; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale.
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four reinjections before becoming secondary nonresponders 
and may require investigations (a frontalis or anti-BoNT-A 
antibody titer test) to determine whether they are resistant 
to the BoNT-A, before they move to BSC. The enforced 
discontinuation after these cycles of nonresponse is mod-
eled using tunnel states in the Markov design. Additionally, 
patients receiving BoNT-A may discontinue treatment due 
to causes such as loss of effect, severe adverse events (AEs), 
or other reasons according to an annual discontinuation rate. 
Once patients discontinue treatment, they move on to BSC. At 
all health states, patients can die. In the nonactive treatment 
(BSC) arm, patients start and remain in BSC state until death.
Dysphagia is a commonly reported AE that may impair 
the patient’s QoL or carry certain management costs. Disu-
tility and costs associated with dysphagia were included in 
the model for the proportion of patients who experience it, 
but it was assumed not to cause treatment discontinuation.
Model inputs
Efficacy inputs
Data on clinical efficacy (improvements in TWSTRS) 
were derived from the Phase III placebo-controlled trial 
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of  abobotulinumtoxinA (NCT00288509).25 In this study, 
compared with placebo, a abobotulinumtoxinA produced 
significant decreases from baseline in the mean TWSTRS 
total scores compared with placebo at week 4 (−15.6, SD: 
2.0 vs −6.7, SD: 2.0; p<0.001) with significant improve-
ments sustained to week 12 (−9.1, SD: 1.7 vs −4.9, SD: 1.7; 
p=0.019).25 The model assumed that within a model cycle, 
which was set to be equal to one injection cycle, responders 
to BoNT-A could experience a sharp improvement in the 
total TWSTRS score by week 4, with this peaking at week 
8, and then waning by week 12. It also assumed that the 
TWSTRS score at the end of each cycle did not return fully 
to the baseline value due to residual benefit from BoNT-A 
as shown in Figure S1. It was also assumed that patients on 
BSC could benefit from minor improvements in TWSTRS 
compared to baseline.
Other clinical inputs such as reinjection interval, annual 
rate of all-cause treatment discontinuation, and AE rates 
for dysphagia per injection are given in Table S1, with cor-
responding assumptions.
Utility inputs
For the model, death was assigned a utility of 0 and 1 repre-
sented a state of perfect health. Utility data were derived from 
the Phase III trial of abobotulinumtoxinA.25 Specifically, the 
relationship between TWSTRS and utility was determined 
using a repeated-measures logistic regression analysis on 
the 36-item Short Form Health Survey and TWSTRS data at 
baseline or week 12 (Table S2, Figure 2). A preference-based 
value set was applied to patient responses to the 36-item 
Short Form Health Survey to obtain utilities. In the model, 
utility was linked at all times to the TWSTRS score such that 
improvement or worsening of TWSTRS corresponded with 
an increasing or decreasing utility. The calculated baseline 
utility and utility gains at weeks 0, 4, 8, and 12 are detailed 
in Table 1.
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Figure 2 Graphical representation of linkage between utility and TWSTRS 
estimated from analysis of abobotulinumtoxinA trial. Data extrapolated from a 
previous study.25
Notes: The line represents the best fit to the available data given by the blue points 
showing reduced utility with higher TWSTRS total score.
Abbreviation: TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale.
Table 1 Discounted costs and health outcomes in base-case analysis
Costs AbobotulinumtoxinA (£) BSC without BoNT-A 
injections (£)
Incremental (AbobotulinumtoxinA 
vs BSC) (£)
Drug cost 5,188 0 5,188
Concomitant medications  
cost
429 488
−59
Drug administration cost 4,600 0 4,600
Disease management cost 6,300 8,869
−2,569
Indirect cost – – –
Total cost 16,517 9,357 7,160
Health outcomes AbobotulinumtoxinA BSC without BoNT-A injections Incremental
Life-years 18.042 18.042 0.000
QALYs 11.970 11.735 0.235
Mean treatment duration with BoNT-A (years) AbobotulinumtoxinA
Mean treatment duration (years) 10.309
Nonresponders 0.575
Responders 9.734
Cost-effectiveness results AbobotulinumtoxinA vs BSC without BoNT-A injections
Incremental QALYs gained 0.235
Incremental costs £7,160
Incremental cost per QALY (ICER) £30,468
Abbreviations: BoNT-A, botulinum neurotoxin type A; BSC, best supportive care; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life-years.
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Resource use and cost inputs
Direct medical costs in the model comprised the value of all 
goods, services, and other resources involved in providing 
the intervention and all current and future consequences 
linked to the disease process. These included primarily drug 
costs, administration costs, and disease management costs 
as outlined in Table 2. All other resources used, concomitant 
medication costs, and unit costs are detailed in Table S1. 
In particular, the model assumed that the drug dose varied 
between first injection and reinjections, as well as among 
health states with different response levels (nonresponders 
and responders). Reinjections were associated with a higher 
dose than first injection, as real-world treatment patterns 
indicate that doctors normally start with the lowest dose and 
increase it gradually in subsequent injections if the patient 
does not respond. Consequently, nonresponders have a higher 
average dose than responders. Model inputs for first injection 
were obtained from the summary of product characteristics 
(SmPC) for each BoNT-A,27–29 while doses and treatment 
intervals for subsequent injections were those suggested by 
clinical experts.
Drug administration costs were incurred for each injec-
tion according to the health care professional who gave 
the BoNT-A injection and the frequency of treatments. 
 Concomitant medication costs were incurred for medications 
used by patients with CD in addition to BoNT-A therapy. Dis-
ease management costs comprised those of  hospitalizations, 
 surgery, or health care professional visits required addition-
ally to those for BoNT-A administration.
Indirect costs primarily included costs associated with 
productivity losses of patients with CD. To quantify the 
economic impact of productivity losses, lost productive time 
(LPT) from Stacy et al (2012)30 was used to estimate the per-
person hours per week associated with reduced performance 
at work (“presenteeism”) and absence from work (“absentee-
ism”) due to disability. The associated indirect costs per week 
were estimated by multiplying the LPT by the average hourly 
income in the UK (given in Table S1). Due to unavailability 
of data, indirect costs for time to doctor office visits and for 
caregivers’ time were not considered.
Analyses
Base-case analysis
The base-case analysis compared the costs and QALYs, 
discounted at 3.5%, of using abobotulinumtoxinA versus 
BSC, from the NHS and PSS perspective over a lifetime 
horizon in a scenario where response is considered as 
at least 20% improvement in TWSTRS total score from 
Table 2 Direct and indirect costs (please refer to Table S1 for further details on the base-case model inputs)
Costs Details Source/assumptions
Direct costs
Drug costs £154 per 500 unit vial at initial dose  
of BoNT-A, 750 units at subsequent 
 doses; £0 for BSC
Dose varied between first injection and reinjections, as well as among 
health states with different response levels (nonresponders and 
responders). Model inputs for drug costs were derived from the BNF,34 
the SmPC of BoNT-A products,27–29 and expert clinical input
Drug administration costs £146 per neurologist visit for each  
cycle of BoNT-A; £0 for BSC
Incurred for each injection according to the treating health care 
professional who administered the BoNT-A injection and the frequency 
of treatments. Estimated using costs from the PSS,35 frequency of visits 
from the US ANCHOR-CD study (Ipsen Pharma, unpublished data, 
2012), and UK clinical experts
Disease management costs £138 per year for BoNT-A; £493  
per year for BSC
Hospitalizations, surgery, or health care professional visits that arise in 
addition to BoNT-A administration visits or costs of not being treated 
with BoNT-As. Calculated based on costs derived from Unit Costs of 
Health and Social Care 2011” published by PSS in the UK and “National 
Schedule of Reference Costs Year 2010–2011” published by Department 
of Health in the UK.35 Frequency of disease management interventions 
was based on consultation with clinical experts in the UK
Indirect costs*
Productivity loss Average hourly wage was £12.76.  
Number of hours lost per week: 
2 hours for BoNT-A; 5 hours for  
BSC
Indirect costs per week were estimated by multiplying the lost 
productivity time by the average hourly income in the UK. Average 
hourly wage was based on data from the ONS26 and the number of hours 
lost derived from published literature30
Note: *Indirect costs are only included as part of alternative scenario analysis.
Abbreviations: ANCHOR-CD, AbobotulinumtoxinA Neurotoxin: Clinical and Health Economics Outcomes Registry in Cervical Dystonia; BNF, British National 
Formulary; BoNT-A, botulinum neurotoxin type A; BSC, best supportive care; ONS, Office for National Statistics; PSS, Personal Social Services; SmPC, summary of product 
characteristics.
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baseline and vial-sharing was not allowed. The base-case 
model parameters are presented in Table S1 alongside their 
assumptions, with the exception of indirect costs, which 
were considered only in an alternative scenario analysis 
described ahead.
Alternative scenario analysis
Alternative scenario analyses were conducted to test the fol-
lowing assumptions: productivity losses incurred by patients 
with CD; sharing of vials; analytic time horizon of 5 years; 
injection cycles as in the SmPCs, specifically, 16 weeks for 
abobotulinumtoxinA,28 10 weeks for incobotulinumtoxinA,29 
10 weeks cycle for onabotulinumtoxinA27; at least 30% 
improvement in TWSTRS from baseline and allowance of 
secondary nonresponse following the initial BoNT-A injec-
tion, or achievement of response at subsequent injection 
cycles for initial nonresponders. The following comparisons 
were also performed: onabotulinumtoxinA versus BSC; 
incobotulinumtoxinA versus BSC; abobotulinumtoxinA 
versus onabotulinumtoxinA; and abobotulinumtoxinA versus 
incobotulinumtoxinA.
One-way sensitivity analysis
To identify model drivers and examine key areas of uncer-
tainty within the model, one-way sensitivity analyses were 
provided for all major model variables. Parameters were 
varied between a minimum and maximum range that was 
determined directly from published data. Where data were not 
available to inform this range, the minimum and maximum 
values were ±20% of the base-case value. Tornado diagrams 
were generated for incremental costs, incremental QALYs 
and ICERs, and incremental net benefit using a £20,000/
QALY threshold. Table S3 lists the parameters varied in 
one-way sensitivity analysis.
Probabilistic sensitivity analysis
To account for multivariate and stochastic uncertainties in 
the model, a probabilistic sensitivity analysis was performed. 
Probabilistic parameters were defined according to appro-
priate statistical distributions to ascertain uncertainty. The 
selection of distributions was dependent on the nature of the 
underlying parameter, with beta distribution being used for 
probabilities and utilities, and gamma distribution used for 
positively valued parameters such as the costs.
The probabilistic sensitivity analysis was run for 5,000 
simulations. The incremental gains in terms of QALYs were 
plotted against incremental costs of abobotulinumtoxinA 
and its comparators on the cost-effectiveness plane. A cost-
effectiveness acceptability curve was generated to show the 
probability of being cost-effective for each treatment over 
a range of willingness-to-pay values for a QALY. Table S4 
lists the distribution of parameters varied in probabilistic 
sensitivity analysis.
Results
Base-case results
The discounted costs and health outcomes for abobotulinum-
toxinA and BSC for the base case are given in Table 1. The 
total incremental QALYs gained from abobotulinumtoxinA 
compared to BSC was 0.235 per patient, with the total incre-
mental cost being £7,160. This corresponds to an ICER of 
£30,468 per QALY gained.
Alternative scenario results
The results of abobotulinumtoxinA versus BSC for the alter-
native scenarios are presented in Table 3. With vial-sharing, 
the total incremental QALYs gained were unchanged but the 
associated total incremental costs were £6,234, correspond-
ing to an ICER of £26,526 per QALY (i.e., lower than the 
base-case ICER). When productivity losses were considered, 
the QALYs remained unchanged but the total incremental 
costs were –£7,311, implying that abobotulinumtoxinA 
usage was cost-saving compared to BSC. Changing the 
time horizon to 5 years resulted in total incremental costs 
of £2,809, incremental QALYs of 0.083, and an ICER of 
£38,117. Considering 5% secondary nonresponders and 25% 
secondary responders resulted in total incremental QALYs 
of 0.247, total incremental costs of £10,072, and an ICER 
of £40,777. With a 16-week reinjection interval for abobotu-
linumtoxinA,28 the incremental costs and QALYs were found 
to be £5,396 and 0.252, respectively, with an associated ICER 
of £21,413. Considering response as 30% improvement in 
TWSTRS from baseline resulted in an ICER of £29,089 (i.e., 
lower than the base-case ICER).
Table S5 presents comparisons of onabotulinumtoxinA 
and incobotulinumtoxinA versus BSC and abobotulinumtox-
inA versus onabotulinumtoxinA and incobotulinumtoxinA 
for 12- and 10-week reinjection intervals. Compared to BSC, 
the ICERs for onabotulinumtoxinA and incobotulinumtoxinA 
were £48,978 and £58,554 for the 12-week injection cycle, 
and £48,625 and £44,933 for the 10-week interval, respec-
tively, due to higher drug-acquisition costs associated with 
onabotulinumtoxinA and incobotulinumtoxinA compared to 
abobotulinumtoxinA.
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One-way sensitivity analysis results
One-way (deterministic) sensitivity analysis was conducted 
on the parameters listed in Table S3. The tornado diagrams 
given in Figures S2–S5 show the most influential param-
eters on outcomes for abobotulinumtoxinA versus BSC. 
Incremental costs were most influenced by the proportion 
of responders to abobotulinumtoxinA at first injection, 
duration of the reinjection interval, and the number of 
cycles of reinjection allowed among primary nonresponders. 
Incremental QALYs and incremental net benefit were most 
sensitive to number of cycles of reinjection allowed amongst 
primary nonresponders and proportion of responders and 
nonresponders to abobotulinumtoxinA at first injection. 
Table 3 Alternative scenario results: abobotulinumtoxinA compared to BSC
Scenario AbobotulinumtoxinA BSC Incremental 
(AbobotulinumtoxinA vs BSC)
Total costs  
(discounted)
QALYs Total costs  
(discounted)
QALYs Total costs  
(discounted)
QALYs ICERs
Base case £16,517 11.970 £9,357 11.735 £7,160 0.235 £30,468
Considering 5% secondary  
nonresponders and 25% secondary 
responders
£19,429 11.982 £9,357 11.735 £10,072 0.247 £40,777
Considering 16 weeks reinjection  
interval for abobotulinumtoxinA*
£14,728 11.948 £9,332 11.696 £5,396 0.252 £21,413
Considering response as ≥30%  
improvement in TWSTRS from  
baseline
£16,222 11.974 £9,357 11.738 £6,865 0.236 £29,089
Considering indirect costs due to  
productivity loss
£61,971 11.970 £69,282 11.735
−£7,311 0.235 Cost-saving
Considering vial-sharing £15,591 11.970 £9,357 11.735 £6,234 0.235 £26,526
Time horizon = 5 years £5,443 2.942 £2,280 2.859 £2,809 0.083 £38,117
Note: *Same reinjection interval (16 weeks) was assumed for BSC.
Abbreviations: BSC, best supportive care; ICERs, incremental cost-effectiveness ratios; QALYs, quality-adjusted life-years; TWSTRS, Toronto Western Spasmodic 
Torticollis Rating Scale.
ICERs were most sensitive to TWSTRS value at baseline 
among BSC and abobotulinumtoxinA patients and the 
number of cycles of reinjection allowed among primary 
nonresponders.
Probabilistic sensitivity analysis results
Results of the probabilistic sensitivity analysis conducted 
for the base case are presented in Figures 3 and 4. The cost-
effectiveness plane shows that, although abobotulinumtoxinA 
is more costly than BSC, it is also more effective. The CEAC 
showed that abobotulinumtoxinA had a 46% probability of 
being cost-effective at a threshold of £20,000 compared to 
BSC without BoNT-A injections.
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Figure 3 Cost-effectiveness planes of incremental costs per QALY of abobotulinumtoxinA versus BSC.
Abbreviation: BSC, best supportive care; QALY, quality-adjusted life-year.
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Discussion
Our economic model showed for patients with CD in the 
UK that abobotulinumtoxinA was cost-effective compared 
to BSC, at a maximum acceptable willingness-to-pay thresh-
old of £30,000 per QALY24 under base-case assumptions. 
Specifically, the treatment provided a lifetime gain of 0.235 
QALYs at an incremental cost of £7,160 and the health 
benefits was attributable to a reduction in the severity of CD 
(as measured by TWSTRS, which correlated directly with 
patients’ utility). In addition, the results remained broadly 
consistent in both testing of alternative scenarios to the 
base cases and across a range of sensitive analyses. Overall, 
therefore, our findings represent a significant development in 
the knowledge of the economic and health benefits of using 
BoNT-As for this indication, given that few other economic 
evaluations of these treatments for CD have been previously 
published.21,31
As with many models, ours had limitations arising from 
data availability and structural assumptions. In terms of 
clinical response, data were available to estimate the propor-
tion of responders and their improvement in TWSTRS total 
score for the first injection cycle from clinical trial25 but not 
for subsequent cycles. Therefore, it was assumed that only 
the first injection determined response, although in clinical 
practice additional responses would probably be achieved 
in subsequent cycles for more patients. Furthermore, there 
was a lack of data on the quantities of abobotulinumtoxinA 
administered and health care resources consumed in man-
aging patients. We made the assumption that the utility–
TWSTRS relationship, which was estimated based on data 
from one cycle of botulinum toxin use, would apply equally 
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Figure 4 Cost-effectiveness acceptability curves of abobotulinumtoxinA and BSC without toxins injections.
Abbreviation: BSC, best supportive care.
to  subsequent cycles, though we cannot know how this 
relationship may differ at later times. Having to extrapolate 
outcomes beyond the timeframe of available clinical data was 
another unavoidable limitation – one commonly encountered 
in this type of evaluation.
A key strength of our study is how it took account of 
productivity gains resulting from effective treatment for 
CD. The importance of CD’s effect on productivity has been 
recognized previously, although studies have not generally 
quantified it suitably for subsequent use in economic evalu-
ations. For instance, a study of almost 300 patients by the 
Finnish Dystonia Association32 found 97 subjects (39%) had 
retired because of CD at a median age of 48 years, while many 
others reported sick leave, reduced productivity, and loss 
of employment.14,33 Similarly, a second study found 53.3% 
of patients with CD reported that employment status was 
negatively affected through reduced hours or responsibilities, 
including 18.9% of patients who had lost employment due 
to CD symptoms.15
Another reason that is essential to demonstrate the 
cost-effectiveness of BoNT-A is that many patients receive 
inappropriate treatment (e.g., physiotherapy alone), given 
that CD is an under-recognized condition and BoNT-As are 
consequently underutilized for CD. To the extent that cost of 
treatment with BoNT-A is a potential barrier, it is important 
to communicate the cost-effectiveness of BoNT-A. In conclu-
sion, we believe that in demonstrating the cost-effectiveness 
of abobotulinumtoxinA as treatment for CD, our study makes 
a compelling case for wider use in the UK of such therapy that 
can benefit patients with this physically and psychologically 
debilitating condition.
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Conclusion
The use of abobotulinumtoxinA in adult patients with CD 
was found to be cost-effective at an acceptable willingness-
to-pay threshold in the UK and also provided additional QoL 
gains. This evidence should help to inform clinical decision 
making and commissioning where BoNT-A therapy is being 
considered as a potential treatment for CD.
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Table S2 Estimates of statistical model linking utility and 
TWSTRS based on analysis of abobotulinumtoxinA trial
Parameter Parameter  
estimate
Parameter
Intercept 1.255
Coefficient for  
TWSTRS
−0.0159
Covariance  
matrix
Intercept Coefficient 
for TWSTRS
Intercept 0.01157
Coefficient for TWSTRS
−0.000234 5.437E-06
Abbreviations: TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale.
Table S3 Parameters included in one-way sensitivity analysis
Parameter/variable name Description Base-case input Low value High value
discH Discount rate for health (%) 0.035 0.028 0.042
discC Discount rate for cost (%) 0.035 0.028 0.042
iAge Age (years) 53.00 42.400 63.600
pMale Gender (% male) 0.37 0.296 0.444
TWSBline_NonResp Mean baseline TWSTRS – nonresponders:  
abobotulinumtoxinA
42.79 34.232 51.348
TWSBline_Resp Mean baseline TWSTRS – responders:  
abobotulinumtoxinA
44.12 35.296 52.944
TWSBline_BSC Mean baseline TWSTRS – BSC 43.63 34.902 52.353
Coeff_TWS Coefficient for TWSTRS
−0.02 −0.019 −0.013
Coeff_Inter Intercept 1.26 1.004 1.506
iReinj_PriNonResp Number of reinjection attempts for primary  
nonresponders before abandoning treatment
6.00 4.800 7.200
iReinj_SecNonResp Number of reinjection attempts for secondary  
nonresponders before abandoning treatment
4.00 3.200 4.800
TWSChangeAt4Wks_Abo_ 
nonresponder
AbobotulinumtoxinA_TWSTRS change from  
baseline at 4 weeks – nonresponders
−0.61 −0.643 −0.583
TWSChangeAt4Wks_Abo_ 
fullresponder
AbobotulinumtoxinA _TWSTRS change from  
baseline at 4 weeks – responders
−20.29 −22.290 −18.290
TWSChangeAt8Wks_Abo_ 
nonresponder
AbobotulinumtoxinA _TWSTRS change from  
baseline at 8 weeks – nonresponders
−0.14 −0.140 −0.136
TWSChangeAt8Wks_Abo_ 
responder
AbobotulinumtoxinA _TWSTRS change from  
baseline at 8 weeks – responders
−18.30 −20.300 −16.300
TWSChangeAt12Wks_Abo_ 
nonresponder
AbobotulinumtoxinA _TWSTRS change from  
baseline at 12 weeks – nonresponders
−0.21 −0.283 −0.143
TWSChangeAt12Wks_Abo_ 
fullresponder
AbobotulinumtoxinA _TWSTRS change from  
baseline at 12 weeks – responders
−9.35 −11.350 −7.350
TWSChangeAt4Wks_BSC BSC_TWSTRS change from baseline at 4 weeks
−4.97 −6.970 −2.970
TWSChangeAt8Wks_BSC BSC_TWSTRS change from baseline at 8 weeks
−4.22 −6.220 −2.220
TWSChangeAt12Wks_BSC BSC_TWSTRS change from baseline at 12  
weeks
−3.32 −5.320 −1.320
distriFirstInj_Abo_ 
nonresponder
Probability of nonresponse at first injection 0.37 0.296 0.444
distriFirstInj_Abo_responder Probability of response at first injection 0.63 0.504 0.756
pAE_Abo AE rate per injection: abobotulinumtoxinA (%) 15% 12% 18%
dFirstInj_Abo AbobotulinumtoxinA _first injection dosage:  
mean dose (unit)
500.00 400.000 600.000
dFirstInj_Ona OnabotulinumtoxinA _first injection dosage:  
mean dose (unit)
200.00 160.000 240.000
dFirstInj_Inco IncobotulinumtoxinA _first injection dosage:  
Mean dose (unit)
200.00 160.000 240.000
dReinj_Abo_nonresponder Average abobotulinumtoxinA reinjection  
dosage: nonresponder (unit)
750.00 600.000 900.000
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Parameter/variable name Description Base-case input Low value High value
dReinj_Abo_responder Average abobotulinumtoxinA reinjection  
dosage: responder (unit)
400.00 320.000 480.000
cDrugFirstInj_Abo AbobotulinumtoxinA _first injection cost (£) 154.00 123.200 184.800
cDrugReinj_Abo_ 
nonresponder
AbobotulinumtoxinA _reinjections cost –  
nonresponder (£)
246.40 197.120 295.680
cDrugReinj_Abo_ 
fullresponder
AbobotulinumtoxinA _reinjections cost –  
responder (£)
154.00 123.200 184.800
cConMed_BoNTA Concomitant Meds Cost_BoNTA (£) 0.05 0.042 0.062
cConMed_BSC Concomitant Meds Cost _BSC (£) 0.07 0.059 0.089
cDrugAdmin Cost Drug Admin (£) 146.00 116.800 175.200
cDisMgt_Abo Cost Disease Management_ 
AbobotulinumtoxinA (£)
31.77 25.419 38.129
cDisMgt_BSC Cost Disease Management _BSC (£) 113.31 90.645 135.967
cAE Cost AEs_BoNTA (£) – – –
cIndirect_BoNTA Cost Indirect_Abo (£) 306.24 244.992 367.488
cIndirect_BSC Cost Indirect_BSC (£) 765.60 612.480 918.720
timeYearsInCycle_Abo Reinjection Interval (years) 0.23 0.184 0.276
Abbreviations: AE, adverse event; BoNTA, botulinum neurotoxin type A; BSC, best supportive care; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale.
Table S4 Parameters included in probabilistic sensitivity analysis
Parameter Distribution
Utility at each TWSTRS score (based on mapping) Multivariate 
normal (Cholesky)
Mean baseline TWSTRS distribution,  
nonresponders and responders at 0, 4, 8,  
12 weeks
Gamma
Transition probability: response to secondary  
nonresponse
Beta
Duration of treatment cycle: abobotulinumtoxinA Gamma
Treatment discontinuation rate per year Gamma
AbobotulinumtoxinA _first injection dosage Gamma
AbobotulinumtoxinA_ reinjection dosage: 
nonresponder
Gamma
AbobotulinumtoxinA_ reinjection dosage:  
responder
Gamma
Setting where drug is administered (distribution)
 Neurologist visit Beta
 Physiotherapist visit Beta
 Nurse visit Beta
Disease management
  Neurologist visit (excluding BoNT-A injection)  
per year
Gamma
 GP visit per year Gamma
Hospitalization rate per year: BoNT-A Beta
Hospitalization rate per year: BSC Beta
Length of stay for hospitalization: BoNT-A Gamma
Length of stay for hospitalization: BSC Gamma
Abbreviations: BSC, best supportive care; BoNT-A, botulinum neurotoxin type A; 
GP, general practitioner; TWSTRS, Toronto Western Spasmodic Torticollis Rating 
Scale.
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Table S5 Alternative scenario results: other comparisons
Scenario OnabotulinumtoxinA BSC Incremental 
(onabotulinumtoxinA vs BSC)
Total costs  
(discounted)
QALYs Total costs  
(discounted)
QALYs Total costs 
(discounted)
QALYs ICERs
Base case £20,573 11.964 £9,357 11.735 £11,216 0.229 £48,978
Considering 10 weeks  
reinjection interval for  
onabotulinumtoxinA*
£21,968 11.954 £9,277 11.693 £12,691 0.261 £48,625
Scenario IncobotulinumtoxinA BSC Incremental 
(IncobotulinumtoxinA vs BSC)
Total costs  
(discounted)
QALYs Total costs  
(discounted)
QALYs Total costs  
(discounted)
QALYs ICERs
Base case £22,473 11.959 £9,357 11.735 £13,116 0.224 £58,554
Considering 10 weeks  
reinjection interval for  
incobotulinumtoxinA*
£21,364 11.962 £9,277 11.693 £12,087 0.269 £44,933
Note: *Same reinjection interval (10 weeks) was assumed for BSC.
Abbreviations: BSC, best supportive care; ICERs, incremental cost-effectiveness ratios; QALYs, quality-adjusted life-years.
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Figure S1 Illustration of QALY gain in first (A) and subsequent cycle (B) when TWSTRS is assumed to have residual benefit at week 12.
Abbreviations: QALYs, quality-adjusted life-years; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale.
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Figure S2 Tornado diagram of one-way sensitivity analysis on incremental cost.
Abbreviations: BSC, best supportive care; BoNT-A, botulinum neurotoxin type A.
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Figure S3 Tornado diagram of one-way sensitivity analysis on incremental benefit.
Abbreviations: BSC, best supportive care; QALY, quality-adjusted life-year; TWS, Toronto Western Spasmodic.
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Figure S4 Tornado diagram of one-way sensitivity analysis on ICER.
Abbreviations: BSC, best supportive care; ICER, incremental cost-effectiveness ratio; TWS, Toronto Western Spasmodic.
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Figure S5 Tornado diagram of one-way sensitivity analysis on incremental net benefit with a willingness-to-pay threshold of £20,000/QALY.
Abbreviations: BSC, best supportive care; INB, incremental net benefit; QALY, quality-adjusted life-year; TWS, Toronto Western Spasmodic.
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